 |
 |

Increased Caudate Dopamine D2 Receptor Availability as a Genetic Marker for Schizophrenia
Jussi Hirvonen, MD;
Theo G. M. van Erp, MA;
Jukka Huttunen, MD;
Sargo Aalto, MSc;
Kjell Någren, PhD;
Matti Huttunen, MD, PhD;
Jouko Lönnqvist, MD, PhD;
Jaakko Kaprio, MD, PhD;
Jarmo Hietala, MD, PhD;
Tyrone D. Cannon, PhD
Arch Gen Psychiatry. 2005;62:371-378.
Context Schizophrenia has a heritability of about 80%, but the detailed molecular genetic basis of the disorder has remained elusive. Relative hyperfunction of the subcortical dopamine system has been previously suggested to be one of the key pathophysiologic mechanisms in schizophrenic psychosis.
Objective To examine the contributions of genetic vulnerability for schizophrenia to the dopamine system in the human brain.
Design Population-based twin cohort study.
Setting Finland.
Participants Six monozygotic and 5 dizygotic unaffected co-twins of patients with schizophrenia were ascertained, along with 4 monozygotic and 3 dizygotic healthy control twins with no family history of psychotic disorders.
Main Outcome Measures Striatal dopamine D2 receptor availability estimated with positron emission tomographic imaging and carbon 11 (11C)labeled raclopride, and performance on neuropsychological tests sensitive to frontal lobe functioning and to schizophrenia vulnerability.
Results Unaffected monozygotic co-twins had increased caudate D2 density compared with unaffected dizygotic co-twins and healthy control twins. Higher D2 receptor binding in caudate was associated with a poor performance on cognitive tasks related to schizophrenia vulnerability in the whole sample.
Conclusions The caudate dopamine D2 receptor up-regulation is related to genetic risk for schizophrenia. Higher dopamine D2 receptor density in caudate is also associated with poorer performance on cognitive tasks involving corticostriatal pathways. This finding suggests that caudate dopamine dysregulation is also a trait phenomenon related to psychosis vulnerability. This pattern of results provides a theoretical rationale for early pharmacologic intervention approaches using dopamine D2 receptor blocking drugs.
Author Affiliations: Departments of Pharmacology and Clinical Pharmacology (Dr Hirvonen) and Psychiatry (Drs J. Huttunen and Hietala), Centre for Cognitive Neuroscience (Mr Aalto), and Turku PET Centre (Drs Hirvonen, J. Huttunen, Någren, and Hietala), University of Turku, Turku, Finland; Departments of Psychology, Psychiatry, and Human Genetics, University of California at Los Angeles School of Medicine (Mr van Erp and Dr Cannon); Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland (Drs M. Huttunen, Lönnqvist and Kaprio); and Department of Public Health, University of Helsinki (Dr Kaprio).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis
HOWES et al.
Br. J. Psychiatry 2007;191:s13-s18.
ABSTRACT
| FULL TEXT
Evidence That the BLOC-1 Protein Dysbindin Modulates Dopamine D2 Receptor Internalization and Signaling But Not D1 Internalization
Iizuka et al.
J. Neurosci. 2007;27:12390-12395.
ABSTRACT
| FULL TEXT
Brain Dopamine D1 Receptors in Twins Discordant for Schizophrenia
Hirvonen et al.
Am. J. Psychiatry 2006;163:1747-1753.
ABSTRACT
| FULL TEXT
|